BioRestorative Therapies
BRTX • NASDAQ
BioRestorative Therapies is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Lance Alstodt, with a market cap of $6.4M.
CEOLance Alstodt
Next Earnings
Upcoming earnings announcement for BioRestorative Therapies
Date
Wednesday, May 13, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.49
Revenue Estimate
$347.5K
Earnings History
Past 12 earnings reports for BioRestorative Therapies
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | Q4 2025 | -$0.32Est: -$0.37 | +13.5% | $19.6KEst: $170.0K | -88.5% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.33Est: -$0.38 | +13.2% | $11.8KEst: $436.0K | -97.3% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.30Est: -$0.41 | +26.8% | $303.0KEst: $284.0K | +6.7% | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.64Est: -$0.32 | -100.0% | $25.0KEst: $380.0K | -93.4% | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$0.20Est: -$0.27 | +25.9% | $43.3KEst: $475.0K | -90.9% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.13Est: -$0.43 | +69.8% | $215.4KEst: $350.0K | -38.5% | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.50Est: -$0.56 | +10.7% | $89.1KEst: $10.0K | +791.0% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.33Est: -$0.51 | +35.3% | $35.0KEst: $30.0K | +16.7% | 10-Q |
| Mar 29, 2024 | Q4 2023 | -$0.57Est: -$0.69 | +17.4% | $19.3KEst: $10.0K | +93.0% | — |
| Nov 13, 2023 | Q3 2023 | -$0.64Est: -$0.68 | +5.9% | $30.7KEst: $30.0K | +2.3% | — |
| Aug 11, 2023 | Q2 2023 | -$0.77Est: -$1.18 | +34.7% | $64.5KEst: $10.0K | +545.0% | — |
| May 12, 2023 | Q1 2023 | -$1.53Est: -$1.26 | -21.4% | $31.3KEst: $31.0K | +1.0% | — |